Document link: Evidence Summary on Subcutaneous Rituximab for the Treatment of Non-Hodgkin’s Lymphoma (Proponents may submit appeals to hta@doh.gov.ph until 18 March 2022.) Document Preview:
Evidence brief for 21 February – 27 February 2022
For the period of 21 February 2021 to 27 February 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 21 February – 27 February 2022
Evidence brief for 14 February – 20 February 2022
For the period of 14 February 2021 to 20 February 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 14 February – 20 February 2022
Evidence brief for 07 February – 13 February 2022
For the period of 07 February 2021 to 13 February 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 07 February – 13 February 2022
Pediatric Vaccination for the prevention of COVID-19 for 5 to 11 age group
HTAC Recommends the Use of Pfizer-BioNTech (10ug/dose) COVID-19 Vaccine for Children 5 to 11 Years Old: Guidance and Conditions for Implementation Released on 11 February 2022 Link to Evidence Summary: Pfizer-BioNTech COVID-19 Vaccine for children 5 to 11 years old COVID-19 Vaccines under Emergency Use Authorization (EUA) The Philippine Food and Drug Administration (FDA) issues an EUA for continue reading : Pediatric Vaccination for the prevention of COVID-19 for 5 to 11 age group